Geert Kersten @GeertKersten1

CEO of cancer company CEL-SCI Corporation (NYSE: CVM). Make the world a better place, make a difference, and take care of your family. Only my personal opinion! Washington, DC Joined May 2020

Tweets

312
Followers

2K
Following

212
Likes

205

Geert Kersten @GeertKersten1

a year ago

Most investments begin in discomfort. That is what a famous investor wrote. oaktreecapital.com/insights/memo/…. We are at that stage because until a few days ago there was no clear regulatory path to market. Now there is. Look at our clinical data. Think longer term for huge returns. $CVM

29 5 24 5K 1

Geert Kersten @GeertKersten1

a year ago

$CVM Thank you for the go-ahead from FDA for the confirmatory trial. We already know how the selected patients did in the completed study. 73% survival with Multikine vs 45% without Multikine. We can help a lot of patients. I believe! So I bought more stock.

10 4 36 5K 3

Geert Kersten @GeertKersten1

a year ago

$CVM At CEL-SCI we are looking forward to a month filled with several very important meetings designed to bring our cancer therapy Multikine to market. We will keep you updated on our progress.

9 5 41 6K 2

Geert Kersten @GeertKersten1

3 years ago

$CVM If I look at our history, things have always taken longer than hoped for, but we were always successful in the end. These results make it clear that our Multikine can really help cancer patients. That is the key, helping cancer patients.

CEL-SCI Corporation @CelSciCorp

3 years ago

3 0 16 15K 0

26 4 34 14K 1

Geert Kersten @GeertKersten1

3 years ago

$CVM If I was a head and neck cancer patient, I surely would want to get the chance to have my expected death rate reduced from 54 to 22%. Nothing else has worked for these patients in ages.

CEL-SCI Corporation @CelSciCorp

3 years ago

$CVM If I was a head and neck cancer patient, I surely would want to get the chance to have my expected death rate reduced from 54 to 22%. Nothing else has worked for these patients in ages.

4 2 30 0 0

25 6 52 0 0

CEL-SCI Corporation @CelSciCorp

3 years ago

CEL-SCI $CVM Corporation Issues Letter to Shareholders #Multikine - businesswire.com/news/home/2022…

7 7 35 0 0

Geert Kersten @GeertKersten1

3 years ago

$CVM We persisted when experts told us that cancer immunotherapy would not work, that head & neck cancer was an impossible to treat disease, yet we have an almost 4 yr survival benefit for patients receiving our Multikine plus surgery and radiation.

17 5 62 0 0

Geert Kersten @GeertKersten1

3 years ago

$CVM We had well over 100 interested physicians review the results of our Phase 3 head and neck cancer study with us today at ASCO 2022. Very positive feed back. Thank you Dr. Talor.

11 12 89 0 1

Download Image

Geert Kersten @GeertKersten1

3 years ago

$CVM I am so proud of our team. An almost 4 year survival benefit in head and neck cancer with no toxicity added. That is why we believe!

Frencheese Investor @dinhvesting

3 years ago

$CVM I am so proud of our team. An almost 4 year survival benefit in head and neck cancer with no toxicity added. That is why we believe!

1 1 12 0 0

Download Image

20 14 79 0 1

Geert Kersten @GeertKersten1

3 years ago

$CVM When you finally learn the details of the huge data set for the Multikine Phase 3 study, think of how this might help cancer patients. That is what will drive things from here on. The rest is background noise.

CEL-SCI Corporation @CelSciCorp

3 years ago

5 5 39 0 0

20 11 73 0 0

Geert Kersten @GeertKersten1

4 years ago

$CVM It is a sad statement for our society when a Company has to defend itself from stock manipulators after creating a novel cancer drug that increases survival from 48 to 62% at 5 yrs with no safety issues, beating all statistics. Unmet medical need, orphan drug status.

CEL-SCI Corporation @CelSciCorp

4 years ago

12 6 36 0 0

69 18 112 0 0

Geert Kersten @GeertKersten1

4 years ago

$CVM We showed survival data exceeding all primary endpoints for 1 of 2 treatment arms with no safety issues. On the call yesterday we showed that this analysis was pre-specified in the protocol and conducted BEFORE unblinding, confirmed by the biostatistician, per the FDA rules

55 10 90 0 0

Geert Kersten @GeertKersten1

4 years ago

$CVM FDA works on the basis of data and clinical benefit. They will decide whether a statistically significant 5 yr. survival difference between 48 and 62% for a terrible unmet need is approvable. Does it help these patients? We believe that it does.

35 8 86 0 0

Geert Kersten @GeertKersten1

4 years ago

$CVM I tip my hat in respect of the short sellers ability to make the great survival benefit with no safety issues look bad. Unreal. This reminds me of when we won the arbitration against Inventiv, a huge win, and the stock declined. I bought over 300,000 shares at $0.84.

50 5 105 0 0

Download Gif

Geert Kersten @GeertKersten1

4 years ago

$CVM Cancer drugs usually work in only a small percentage of people and have a lot of safety problems. They still get approved. We think that we have done much better than that. IS IT HELPING THE PATIENTS?

33 14 121 0 0

Geert Kersten @GeertKersten1

4 years ago

$CVM Such amount of misinformation. Great data and we believe very approvable. The analysis we did was included in the protocol and the Statistical Analysis Plan and is therefore acceptable to FDA. The group is 1 of 2 and represents over 150,000 patients.

27 21 132 0 1

Geert Kersten @GeertKersten1

4 years ago

The $CVM Phase 3 study shows great overall survival benefit (ITT) of 14.1% (62.7% vs 48.6%) at 5 yrs. No safety issues. Outstanding p=0.0236, Hazard ratio=0.68. Survival increases over time. We plan to seek FDA approval for this unmet need.

CEL-SCI Corporation @CelSciCorp

4 years ago

13 21 76 0 0

37 19 133 0 0

Geert Kersten @GeertKersten1

4 years ago

We $CVM fight for a better way to treat cancer every day. Be a part of our team and help us with your votes.

CEL-SCI Corporation @CelSciCorp

4 years ago

We $CVM fight for a better way to treat cancer every day. Be a part of our team and help us with your votes.

4 3 38 0 0

17 7 73 0 0

Geert Kersten @GeertKersten1

4 years ago

My team and I have invested a life time and huge amounts of money into $CVM trying to create a super safe cancer drug that will do something that has not ever been done. Final data almost here. Why such hate from some? Wishing a better way of treating cancer ill? So wrong!!!

36 23 161 0 1

Download Gif

Geert Kersten @GeertKersten1

4 years ago

$CVM For those manipulative people who claim that we are trying to delay the final analysis of our huge cancer study. Everything is messed up thanks to COVID. Despite all of that our CROs have met one milestone after another while maintaining quality. cnbc.com/2021/06/13/hom…